Perspectives on the Designation of Oligonucleotide Starting Materials

The designation of starting materials (SMs) for pharmaceuticals has been a topic of great interest and debate since the first ICH quality guidance was published. The increase in the number and variety of commercialized oligonucleotides (antisense oligonucleotides—ASOs, small interfering RNAs—siRNAs,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiesman, William F., McPherson, Andrew K., Diorazio, Louis J., Van den Bergh, Leo, Smith, Peter D., Northall, John M., Fettes, Alec, Wang, Tiejun, Mehlmann, Martin, Raza, Syed, Held, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Issues in Development
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997719/
https://www.ncbi.nlm.nih.gov/pubmed/33534646
http://dx.doi.org/10.1089/nat.2020.0909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997719/
https://www.ncbi.nlm.nih.gov/pubmed/33534646
http://dx.doi.org/10.1089/nat.2020.0909

Ejemplares similares